Bevacizumab-induced hypertension: Clinical presentation and molecular understanding-Reference-Cited by-同舟云学术

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding

Published:2018-02 Issue: Volume:182 Page:152-160
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Li Megan,Kroetz Deanna L.

Funder

Alliance Clinical Trial Foundation

Pharmacogenomics Development Fund

NIH

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference131 articles.

1. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients;Abajo;British Journal of Cancer,2010

2. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: An updated meta-analysis;An;European Journal of Clinical Pharmacology,2010

3. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes;Awata;Diabetes,2002

4. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling;Baffert;American Journal of Physiology: Heart and Circulatory Physiology,2006

5. Pretruncal subarachnoid hemorrhage and high cerebral blood flow velocities with bevacizumab therapy;Baizabal-Carvallo;Clinical Neuropharmacology,2010

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The analysis of multiple omics and examination of pathological images revealed the prognostic and therapeutic significances of CD93 in lung squamous cell carcinoma;Life Sciences;2024-02

2. Systemic bevacizumab for treatment of recurrent respiratory papillomatosis;European Archives of Oto-Rhino-Laryngology;2024-01-05

3. Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab;Frontiers in Oncology;2024-01-04

4. Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease;Translational Neurodegeneration;2024-01-03

5. Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials;Journal of Pharmaceutical Health Care and Sciences;2024-01-02